Actively Recruiting
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
Led by The Third Xiangya Hospital of Central South University · Updated on 2026-02-19
600
Participants Needed
1
Research Sites
261 weeks
Total Duration
On this page
Sponsors
T
The Third Xiangya Hospital of Central South University
Lead Sponsor
C
Changsha Hospital for Maternal and Child Health Care
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are exploring the best treatment approach for retained products of pregnancy, a condition where tissue remains in the uterus after pregnancy. This study aims to see if managing the condition with medication and waiting for the right time to perform surgery reduces the risk of intrauterine adhesions, which can affect fertility. The study is observational and compares this drug-assisted expectant management to immediate surgical treatment. Participants will be assigned to one of two groups: one group will have immediate hysteroscopic removal of pregnancy tissue under anesthesia, while the other group will receive medication and careful monitoring until surgery is needed or the condition resolves. The medication includes hormone therapy and herbal treatments, with regular ultrasound and blood tests to guide timing for surgery if necessary. During the study, participants will be closely monitored with ultrasound scans and blood tests to assess healing and complications. Researchers will track outcomes such as the presence of uterine adhesions three months after treatment, need for additional surgery, pregnancy rates within one year, bleeding, infections, blood loss during surgery, and uterine lining thickness. Participants will be followed up to one year after treatment to observe these outcomes and overall reproductive health.
CONDITIONS
Brief Title
A Prospective Multicenter Observational Real-world Study of Retained Products of Conception
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of retained products of conception
- Ultrasound showing a lesion with a maximum diameter of at least 0.5 cm
- Female participants aged 18 to 45 years
You will not qualify if you...
- Active bleeding requiring immediate surgical intervention
- Obvious infection
- Severe organ dysfunction, including coagulation dysfunction
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to at least 4 weeks or until surgery is needed
Participants with no contraindications take oral medication and undergo regular blood tests and ultrasounds to monitor their condition until a preset surgery time or resolution criteria are met.
Weekly visits for blood tests and every 2 to 3 weeks for ultrasound
Duration - Single day procedure with immediate post-operative care
Participants undergo hysteroscopic removal of pregnancy products under anesthesia as a surgical procedure.
1 hospitalization and surgical procedure visit
Duration - Up to 12 months post-treatment
Participants are monitored for surgical outcomes including intrauterine adhesions, blood loss, and pregnancy outcomes up to 1 year after treatment.
Periodic visits up to 3 months for clinical assessments and follow-up visits for pregnancy outcomes up to 1 year
Trial Site Locations
Total: 1 location
1
The Third Xiangya Hospital of Central South University
Changsha, Hunan, China, 410013
Actively Recruiting
Research Team
D
Dabao MD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here